pharma · Kidney Dysfunction · Obesity
LianBio
Jian Li
Jian Li is a pharma organization headquartered in CN. Primary therapeutic focus areas include Kidney Dysfunction, Obesity, Fibrosis, Ebola Virus Disease, Bladder Cancer. NovaPharmaNews links 28 clinical program(s), 0 dru
CN HQ
2019 Founded
47 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2019
- Employees
- 47
- Programs
- 28
- Drugs
- 40
- Patents
- 0
HRS-2329 Tablet
Phase 1 · small molecule · Advanced Solid Tumors Harboring RAS Mutations or Amplifications
HRS-2329 Tablet for Advanced Solid Tumors Harboring RAS Mutations or Amplifications is a Phase 1 program (small_molecule) at Jian Li with 1 ClinicalTrials.gov record(s).
Internal code HRS-2329-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Jian Li
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Advanced Solid Tumors Harboring RAS Mutations or Amplifications
- Status
- active
- Trials
- 1